Jubilant Pharma to redeem $200 million 6% senior notes due 2024

By Mary-Katherine Stinson

Lexington, Ky., July 14 – Jubilant Pharma Ltd. issued a notice of conditional redemption for its $200 million 6% senior notes due 2024 (ISIN: XS1958658509), according to a notice Thursday.

The notes will be redeemed at 103 plus interest on Aug. 18.

The company is exercising its option to redeem the notes in full conditioned upon the consummation of a certain loan facility agreement. If closing and funding does not occur prior to the redemption date, the offer will be rescinded.

Following the redemption, the notes will be canceled and none will remain outstanding.

The issuer is a Singapore-based subsidiary of Indian pharmaceutical company Jubilant Life Sciences Ltd.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.